Scotiabank Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $80.00

Sarepta Therapeutics (NASDAQ:SRPT) had its target price cut by Scotiabank from $105.00 to $80.00 in a research note released on Thursday,Benzinga reports. They currently have a sector perform rating on the biotechnology company’s stock.

SRPT has been the topic of several other research reports. Royal Bank of Canada lowered their target price on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Piper Sandler dropped their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. HC Wainwright reissued a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a report on Wednesday. Deutsche Bank Aktiengesellschaft dropped their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $167.41.

Sarepta Therapeutics Trading Up 0.9 %

Shares of SRPT stock opened at $74.10 on Thursday. The company has a market capitalization of $7.19 billion, a P/E ratio of 59.28 and a beta of 0.79. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The business’s 50 day moving average is $107.19 and its two-hundred day moving average is $118.00. Sarepta Therapeutics has a twelve month low of $73.05 and a twelve month high of $173.25.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 7.70% of the stock is currently owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Sarepta Therapeutics by 4.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company’s stock worth $571,000 after purchasing an additional 218 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at about $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Sarepta Therapeutics by 11.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company’s stock valued at $36,392,000 after acquiring an additional 31,098 shares during the last quarter. Woodline Partners LP purchased a new position in shares of Sarepta Therapeutics during the 4th quarter worth about $5,713,000. Finally, Vestal Point Capital LP acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter worth approximately $30,398,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.